{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:10:13Z","timestamp":1778595013175,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T00:00:00Z","timestamp":1171497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2007,10,30]]},"DOI":"10.1007\/s10549-007-9518-7","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T10:14:25Z","timestamp":1171448065000},"page":"315-318","source":"Crossref","is-referenced-by-count":27,"title":["Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature"],"prefix":"10.1007","volume":"106","author":[{"given":"Komal","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,15]]},"reference":[{"issue":"24","key":"9518_CR1","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"E Ian","year":"2003","unstructured":"Ian E, Smith MD, Mitch Dowsett (2003) Aromatase inhibitors in breast cancer. NEJM 348(24):2431\u20132442","journal-title":"NEJM"},{"issue":"6","key":"9518_CR2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/107327480200900606","volume":"9","author":"E Diana","year":"2002","unstructured":"Diana E, Lake MD, Clifford Hudis MD (2002) Aromatse inhibitors in breast cancer: an update. Cancer Control 9(6):490\u2013498","journal-title":"Cancer Control"},{"key":"9518_CR3","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","volume":"19","author":"H Mouridsen","year":"2001","unstructured":"Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596\u20132606 [Erratum, J Clin Oncol 2001; 19:3302.][Abstract\/Full\u00a0Text]","journal-title":"J Clin Oncol"},{"key":"9518_CR4","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","volume":"18","author":"J Bonneterre","year":"2000","unstructured":"Bonneterre J, Thurlimann B, Robertson JFR et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748\u20133757 [Abstract\/Full\u00a0Text]","journal-title":"J Clin Oncol"},{"key":"9518_CR5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"ATAC Trialists\u2019 Group","year":"2002","unstructured":"ATAC Trialists\u2019 Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131\u20132139 [Erratum, Lancet 2002; 360:1520.][CrossRef][ISI][Medline]","journal-title":"Lancet"},{"issue":"26","key":"9518_CR6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1056\/NEJMe058273","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A (2005) Breast International Group (BIG) 1\u201398 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2807\u20132809","journal-title":"N Engl J Med"},{"key":"9518_CR7","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"M Baum","year":"2003","unstructured":"Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802\u20131810","journal-title":"Cancer"},{"issue":"1\u20135","key":"9518_CR8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsbmb.2005.04.009","volume":"95","author":"Eastell Richard","year":"2005","unstructured":"Richard Eastell, Rosemary Hannon (2005) Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 95(1\u20135):151\u2013154","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9518_CR9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802","journal-title":"N Engl J Med"},{"key":"9518_CR10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of Exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","journal-title":"N Engl J Med"},{"key":"9518_CR11","unstructured":"http:\/\/www.cancercare.on.ca\/pdfmedicationinfo\/Letrozole.pdf, http:\/\/www.cancercare.onca\/pdfmedicationinfo\/Anastrozole.pdf , http:\/\/www.cancercare.onca\/pdfmedicationinfo\/Exesmestane.pdf ."},{"key":"9518_CR12","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","volume":"19","author":"MJ Ellis","year":"2001","unstructured":"Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808\u20133816","journal-title":"J Clin Oncol"},{"key":"9518_CR13","first-page":"6523","volume":"63","author":"MJ Ellis","year":"2003","unstructured":"Ellis MJ, Coop A, Singh B et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1\/2 expression status. Cancer Res 63:6523\u20136531","journal-title":"Cancer Res"},{"key":"9518_CR14","unstructured":"Dowsett M (2003) On behalf of the ATAC trialists\u2019 group Royal Marsden Hospital, London, United Kingdom Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. 26th annual San Antonio breast cancer symposium December 2003"},{"key":"9518_CR15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/ard.2004.023150","volume":"64","author":"H Shoda","year":"2005","unstructured":"Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K (2005) Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. Ann Rheum Diseases 64:651\u2013652","journal-title":"Ann Rheum Diseases"},{"key":"9518_CR16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7326\/0003-4819-112-12-965_2","volume":"112","author":"F Drago","year":"1990","unstructured":"Drago F, Arditi M, Rebora A (1990) Tamoxifen and purpuric vasculitis. Ann Int Med 112:965\u2013966","journal-title":"Ann Int Med"},{"issue":"1","key":"9518_CR17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.142.1.70","volume":"142","author":"D Sereda","year":"2006","unstructured":"Sereda D, Werth VP (2006) Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 142(1):70\u201372","journal-title":"Arch Dermatol"},{"key":"9518_CR18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2265.2001.01276.x","volume":"54","author":"MJ Reed","year":"2001","unstructured":"Reed MJ, Purohit A (2001) Review: aromatase regulation and breast cancer. Clinical Endocrinol 54:563\u2013571","journal-title":"Clinical Endocrinol"},{"key":"9518_CR19","doi-asserted-by":"crossref","unstructured":"Yuri Yamaguchi1, Hiroyuki Takei3, Kimito Suemasu3, Yasuhito Kobayashi2, Masafumi Kurosumi2, Nobuhiro Harada4, Shin-ichi Hayashi (2005) Tumor\u2013Stromal interaction through the estrogen-signaling pathway in human breast cancer: cell and tumor biology. Cancer Res 65:4653\u20134662","DOI":"10.1158\/0008-5472.CAN-04-3236"},{"issue":"1","key":"9518_CR20","first-page":"18","volume":"81","author":"Labunski Svenja","year":"2001","unstructured":"Svenja Labunski, Guido Posern, Stephan Ludwig, Kundt G, Br\u00f6cker Eva-B, Manfred Kunz (2001) Tumour necrosis factor\u2014a promoter polymorphism in erythema nodosum. Acta Dermato-Venereologica 81(1):18\u201321","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"9518_CR21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1365-2249.1998.00510.x","volume":"111","author":"EP Sampio","year":"1998","unstructured":"Sampio EP, Moraes MO, Nery JAC, Moraes, Santos AR, Matos HC, Sarno EN (1998) Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol 111(2):300\u2013308 (9)","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"9518_CR22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100670050159","volume":"19","author":"DN Psychos","year":"2000","unstructured":"Psychos DN, Voulgari PV, Skopouli FN, Drosos AA, Moutsopoulos HM (2000) Erythema nodosum: the underlying conditions. Clin Rheumatol 19(3):212\u2013216","journal-title":"Clin Rheumatol"},{"issue":"6\u20137","key":"9518_CR23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/00365540410027184","volume":"36","author":"A Mert","year":"2004","unstructured":"Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R (2004) Erythema nodosum: an experience of 10\u00a0years. Scand J Infect Dis 36(6\u20137):424\u2013427","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"9518_CR24","first-page":"114","volume":"76","author":"Sullivan Robert","year":"2005","unstructured":"Robert Sullivan, Holly Clowers-Webb, Mark DP, Davis (2005) Erythema Nodosum: a presenting sign of Acute Myelogenous Leukemia. Cutis 76(2):114\u2013116","journal-title":"Cutis"},{"key":"9518_CR25","unstructured":"Luis Requena1, Celia Requena2 (\u2013) 1. Department of Dermatology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Universidad Aut\u00f3noma, Madrid, Spain; and 2. Department of Dermatology, Hospital General Universitario, Universidad de Valencia, Valencia, SpainErythema Nodosum. Dermatol Online J 8(1):4"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-007-9518-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9518-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:48Z","timestamp":1559233728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-007-9518-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,15]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,10,30]]}},"alternative-id":["9518"],"URL":"https:\/\/doi.org\/10.1007\/s10549-007-9518-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,15]]}}}